CN103039977A - Healthcare food with functions of immunity improvement and hypoxia tolerance and preparation method thereof - Google Patents
Healthcare food with functions of immunity improvement and hypoxia tolerance and preparation method thereof Download PDFInfo
- Publication number
- CN103039977A CN103039977A CN2012105165073A CN201210516507A CN103039977A CN 103039977 A CN103039977 A CN 103039977A CN 2012105165073 A CN2012105165073 A CN 2012105165073A CN 201210516507 A CN201210516507 A CN 201210516507A CN 103039977 A CN103039977 A CN 103039977A
- Authority
- CN
- China
- Prior art keywords
- mouse
- healthcare food
- immunity
- health food
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses healthcare food with functions of immunity improvement and hypoxia tolerance. The healthcare food consists of the following components in percentage by weight: 5-45% of gingko nut, 5-30% of salvia miltiorrhiza, 10-50% of sea buckthorn, 5-20% of rhodiola root and 5-20% of panax notoginseng. Meanwhile, the invention further discloses a preparation method of the healthcare food. According to the healthcare food and the preparation method of the healthcare food, natural traditional Chinese medicines are adopted as raw materials, and side effects can not be caused while the immunity improvement and the hypoxia tolerance are achieved, thereby being suitable for people of all ages; and meanwhile, the preparation method of the healthcare food is simple, and the change on the natures of all raw materials can not be caused, so that the healthcare food can be stored for a long time.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of health food that has simultaneously raising immunity and resisting oxygen lack and preparation method thereof.
Background technology
Immunity is the defense mechanism of human body self, be human body identification and any foreign matter (virus, bacterium etc.) of eliminating external intrusion, process the ability of self cell and identification and processing vivo mutations cell and the virus infected cell of old and feeble, damage, death, sex change.Immune dysfunction or when low can reduce body to anti-infectious ability, reduces identification and removes the histocyte ability of self aging, reduces and kills and wounds and remove abnormal sudden change cell ability in vivo, causes the decline of human body premunition and vis medicatrix naturae.And modern society, the quickening of rhythm of life, the increase of competitive pressure, every day, the working and learning meeting of anxiety made body be in the overdraw state, as can not get having a rest timely and adjusting, and accumulated over a long period, will the Immunosuppression function; Simultaneously, nervous working and learning allow the more people instant fast food of having to, and cause the unbalance of endotrophic element, if body is in this state for a long time, immunity of organisms are descended, and finally cause the sub-health state of body.
In addition, social development is day by day rapid, and people's life stress also generally strengthens, and rhythm of life is accelerated, increasingly competitive, powerful work and large amount of exercise person, operator, tumor patient, person lower for the resistance, Hyperlipidemia person easily produce anoxic in anaerobic environment.
Therefore, take in to improve immunity health food and the health food of anti-the anoxic and be sought after, certainly, not only had the health food that improves immunity but also resisting oxygen lack is arranged then more practical if can provide a kind of.
Summary of the invention
Make eye bright: the object of the invention is to for the deficiencies in the prior art, a kind of health food that improves immunity and resisting oxygen lack that has simultaneously is provided.
Another object of the present invention is to provide the preparation method of above-mentioned health food.
Technical scheme: in order to achieve the above object, the present invention specifically is achieved like this: a kind of have the health food that improves immunity and resisting oxygen lack simultaneously, is comprised of the component of following percentage by weight: 5 ~ 45% ginkgo, 5 ~ 30% the red sage root, 10 ~ 50% sea-buckthorn, 5 ~ 20% rhodiola root and 5 ~ 20% pseudo-ginseng.
Preferably, the component by following percentage by weight forms: 25% ginkgo, 18% the red sage root, 33% sea-buckthorn, 12% rhodiola root and 12% pseudo-ginseng.
The present invention can make tablet, capsule, oral liquid or soft capsule.
Prepare the above-mentioned method that has simultaneously the health food that improves immunity and resisting oxygen lack, may further comprise the steps: measure each raw material by prescription, add the dolomol of raw material gross weight 1 ~ 2% and 1 ~ 2% silica, crushing screening, mixed 15 ~ 20 minutes, and poured into capsule and get final product.
Wherein, described sieve≤100 orders.
Beneficial effect: it is raw material that the present invention adopts natural traditional Chinese medicine, when reaching raising immunity, resisting oxygen lack, can not have side effects, and is fit to all age group crowd; Simultaneously, preparation method of the present invention is simple, can not cause the variation of each feedstock property, can long preservation.
The specific embodiment
Embodiment 1:
Get percetage by weight and be 40% ginkgo, 30% the red sage root, 10% sea-buckthorn, 5% rhodiola root and 15% pseudo-ginseng, pulverized 100 mesh sieves, add the dolomol of raw material gross weight 1% and 2% silica, mixed 15 minutes, pour into capsule.
Embodiment 2:
Get percetage by weight and be 45% ginkgo, 10% the red sage root, 20% sea-buckthorn, 20% rhodiola root and 5% pseudo-ginseng, pulverized 100 mesh sieves, add the dolomol of raw material gross weight 2% and 2% silica, mixed 16 minutes, pour into soft capsule.
Embodiment 3:
Get percetage by weight and be 30% ginkgo, 5% the red sage root, 30% sea-buckthorn, 15% rhodiola root and 20% pseudo-ginseng, pulverized 80 mesh sieves, add the dolomol of raw material gross weight 2% and 1% silica, mixed 20 minutes, make tablet.
Embodiment 4:
Get percetage by weight and be 15% ginkgo, 20% the red sage root, 40% sea-buckthorn, 12% rhodiola root and 13% pseudo-ginseng, pulverized 80 mesh sieves, add the dolomol of raw material gross weight 1% and 1% silica, mixed 18 minutes, pour into capsule.
Embodiment 5:
Get percetage by weight and be 5% ginkgo, 25% the red sage root, 50% sea-buckthorn, 8% rhodiola root and 12% pseudo-ginseng, pulverized 100 mesh sieves, add the dolomol of raw material gross weight 1% and 2% silica, mixed 15 minutes, with being encapsulated in ampoule behind 10 ~ 20 times the distilled water diluting.
Embodiment 6:
The present invention improves the immunity function experimental study
1. material
1.1 sample: provided by the Wuxi City health bio tech ltd of being bestowed by heaven.
1.2 animal used as test
160 of Kunming mouses, entirely female, body weight 18-22g.
2. experimental technique
2.1 dosage is selected
Tested material is established 400mg/kg.BW, 800mg/kg.BW, three dosage groups of 1200 mg/kg.BW (be equivalent to respectively human body recommended intake 10 times, 20 times, 30 times), take by weighing respectively 10.00g, 20.00g, 30.00g tested material adding distil water to the 250ml mixing, stored refrigerated, be finished again and join, other establishes the edible vegetable oil negative control group, every group of 40 animals.Be divided into immune one group, two groups, three groups, four groups, wherein one group is used for Turnover of Mouse Peritoneal Macrophages and engulfs the chicken red blood cell experiment; Two groups are used for NK cytoactive detection and lymphocyte transformation experiment; Three groups are used for antibody-producting cell experiment, serum hemolysin mensuration and delayed allergy; Four groups are used for mouse carbon and clean up experiment.Mouse gives 30 days continuously by per os gavage of 10 mg/kg.BW body weight, claims weekly body weight one time, adjusts the gavage volume.
2.2 experimental procedure
2.2.1 mouse carbon clearance test: gavage is after 30 days continuously, in the india ink of mouse tail vein injection with 4 times of normal saline dilutions, immediately timing after pressing 0.1ml/10g prepared Chinese ink and injecting is after injecting prepared Chinese ink the 2nd, 10min gets blood 20 μ l from the angular vein clump respectively, is added to 2mlNa
2CO
3In the solution, with Na
2CO
3Solution is made blank, measures OD value at the 600nm place with 723 spectrophotometers.Put to death mouse after getting blood, get liver, spleen is weighed, calculate phagocytic index.
2.2.2 Turnover of Mouse Peritoneal Macrophages is engulfed chicken red blood cell experiment (half intracorporal method): gavage is after 30 days continuously, the chicken erythrocyte suspension 1ml of every mouse peritoneal injection 20%, after 30 minutes, the cervical vertebra dislocation is put to death, be fixed on the mouse plate, abdominal skin is cut off in the center, through Intraperitoneal injection physiological saline 2ml, rotated the mouse plate 1 minute, sucking-off abdominal cavity washing lotion 1ml, mean droplet is on 2 slides, put 37 ℃ in wet box 30 minutes, and took out in the physiological saline rinsing, dry, fixing, 4%GiemsaPBS dyeing 3 minutes, the distilled water rinsing is dried, microscopy.Calculate phagocytic percentage and phagocytic index.
2.2.3 delayed allergy (DTH) (the sufficient sole of the foot thickens method): gavage is after 30 days, inject the every mouse of 2% hematocrit SRBC(0.2ml/ to mouse peritoneal) sensitization is after 4 days, measure left back sufficient sole of the foot thickness, and then measuring point hypodermic injection 20%(v/v) the every mouse of SRBC(20 μ l/), 24h measures left back sufficient sole of the foot thickness after injection, same position is measured three times, averages, and represents the degree of DTH with sufficient sole of the foot thickness difference (swelling degree of the paw) before and after attacking.
2.2.4ConA the mouse lymphocyte conversion test (mtt assay) of inducing: at first carry out the preparation of splenocyte suspension.Cell concentration is adjusted into 3 * 10
6Individual/ml, then cell suspension is divided two holes to add in 24 well culture plates, every hole 1ml, a hole adds 75 μ lConA liquid, and another hole compares, and puts 5%CO
237 ℃ of cultivations of incubator 72h.Cultivate and finish front 4h, every hole sucks gently supernatant 0.7ml and adds the RPMI1640 nutrient solution that 0.7ml does not contain calf serum, add simultaneously MTT (5mg/ml) 50 μ l/ holes and continue to cultivate 4h, after cultivating end, every hole adds 1ml acid isopropyl alcohol, purple crystal is dissolved fully, then every hole liquid is moved in the cuvette, with 723 spectrophotometers in 570nm wavelength place's colorimetric estimation OD value.
2.2.5 antibody-producting cell detects (Jernr improves slide method): gavage is after 30 days continuously, every mouse peritoneal is injected 2% hematocrit SRBC0.2ml, the mouse cervical vertebra dislocation of immunity after 5 days half put to death, take out spleen and be placed in the plate that fills Hank ' s liquid, make splenocyte suspension.Agarose is made into 1% aqueous solution, and 30min is boiled in water-bath, mix with the double Hank ' s of equivalent liquid, and the packing small test tube, every pipe 0.5ml adds 10%(S again in pipe
AThe buffer solution preparation) hematocrit SRBC50 μ l, each 20 μ l of splenocyte suspension do two Duplicate Samples, rapidly behind the mixing, be poured on the agarose thin layer slide, after agar solidifies, the slide level buckled be placed on the horse, put into CO2gas incubator and hatch 1.5h, then complement is joined in the slide frame groove, continue incubation 1.5h, counting hemolysis plaque number.
2.2.6 serum hemolysin is measured (Hemagglutination Method): in continuous gavage after 30 days, every mouse peritoneal injection 2%SRBC0.2ml immunity, continue gavage after 5 days, extract eyeball and get blood in centrifuge tube, place 1h, peel off, the centrifugal 10min of 2000r/min collects serum, with physiological saline serum is made doubling dilution, every part of dilution 12 holes place blood-coagulation-board with the dilution serum of difference, every hole 100 μ l, add again 0.5%SRBC suspension 100 μ l, mixing is put observed result behind wet 37 ℃ of 3h of box, records the aggegation degree in every hole.The calculating antibody product.
2.2.7NK cytoactive detection (lactate dehydrogenase L DH determination method): continuously gavage is after 30 days, and animal is put to death in the cervical vertebra dislocation, takes out spleen, tears up, cross 200 eye mesh screens after, use Hank ' s liquid to wash 3 times, be made into 2 * 10 with complete RPMI1640 nutrient solution
7Individual/the ml cell suspension.The cell suspension of each mouse is got 300 μ l divide 3 holes to place 96 well culture plates, every hole 100 μ l, every hole adds target cell (YAC-1 cell, 4 * 10
5Individual/ml) 100 μ l, do simultaneously each 8 hole of target cell Spontaneous release hole (target cell 100 μ l+ nutrient solutions 100 μ l) and maximum release aperture (target cell 100 μ l+2.5%Triton100 μ l), 37 ℃ of 5%CO
2Cultivated 4 hours, and took out the centrifugal 5min of 1500r/min.Each hole supernatant 100 μ l is placed another culture plate, and every hole adds 100 μ l matrix liquid again, adds the HCL30 μ l cessation reaction of 1mol/L after 10 minutes, measures the OD value at the 490nm place, calculates NK cytoactive rate.
3. test data is added up
Test data adopts SPSS10.0 for Windows software kit to process.The data of control group and dosage group are through the variance test of homogeneity, and variance is neat, carry out variance analysis,, then compare in twos with the Dunnett method less than 0.05 such as the P value; If heterogeneity of variance then carries out data transaction, and is still uneven, use rank test instead, less than 0.05, then use Dunnett ' sT3 method to compare in twos (P〉0.05 for non-significant difference, P＜0.05 is significant difference) such as the P value.
4. result
4.1 the present invention sees Table 1-4 to the impact of Mouse Weight.
Table 1 respectively organize mouse initial body weight (
)
Table 2 respectively organize mouse the body weight in mid-term (
)
Table 3 respectively organize mouse the end body weight (
)
The impact that table 4 the present invention increases weight on Mouse Weight (
)
By table 1-4 as seen, the initial body weight of one group, immune two groups of the present invention immunity, immune three groups and immune four groups of mouse is compared with negative control group, through the variance test of homogeneity, variance neat (P〉0.05), and the results of analysis of variance (P〉0.05), illustrate that the initial body weight of respectively organizing between mouse and the negative control group is balanced.Three dosage group mouse test mid-terms, the body weight in latter stage and the growths of duration of test Mouse Weight are compared with negative control group, learn by statistics and process, there was no significant difference (P〉0.05), i.e. the present invention on the body weight gain of mouse without impact.
4.2 the present invention is on the impact of mouse monokaryon-macrophage phagocytic function
Table 5 the present invention on mouse monokaryon-macrophage carbon clean up function impact (
)
By as seen from Table 5, gavage is after 30 days continuously, and the carbon of three dosage group mouse is cleaned up ability and compared with negative control group, and learn by statistics and process, there was no significant difference (P〉0.05).
Table 6 the present invention on mouse macrophage engulf the chicken red blood cell ability impact (
)
By as seen from Table 6, gavage is after 30 days continuously, and the phagocytic rate of three dosage treated animals is compared with negative control group with phagocytic index, learns by statistics and processes, and middle and high dosage group phagocytic index has significant difference (P＜0.05).
By table 5, as seen from Table 6, the present invention is positive to mouse monokaryon-macrophage phagocytic function test result.
4.3 the present invention is on the impact of mouse cell immunity
Table 7 the present invention on the impact of mouse delayed allergy (DTH) (
)
By as seen from Table 7, gavage is after 30 days continuously, and the swelling degree of the paw of three dosage group mouse is compared with negative control group, and learn by statistics and process, there was no significant difference (P〉0.05)
The impact of the mouse lymphocyte conversion test that table 8 the present invention induces ConA (
)
By as seen from Table 8, the gavage mouse is after 30 days continuously, and the lymphopoiesis ability of three dosage group mouse is compared with negative control, and learn by statistics and process, there was no significant difference (P〉0.05).
By table 7, the present invention is negative to mouse cell immunity test result as seen from Table 8.
4.4 the present invention is on the impact of mouse humoral immune
Table 9 the present invention on the impact of mouse antibodies cellulation (
)
By as seen from Table 9, gavage is after 30 days continuously, and the hemolysis plaque number of three dosage group mouse is compared with negative control, learns by statistics and processes, and low, middle dosage group has significant difference (P＜0.05).
Table 10 the present invention on the impact of mice serum hemolysin (
)
By as seen from Table 10, gavage is after 30 days continuously, and the antibody product of three dosage group mouse is compared with negative control group, learns by statistics and processes, and low dose group has utmost point significant difference (P＜0.05)
By table 9, as seen from Table 10, the present invention is positive to the mouse humoral immune result of the test.
4.5 the present invention is on the impact of NK cells in mice activity
Table 11 the present invention on the impact of NK cells in mice activity (
)
By as seen from Table 11, gavage is after 30 days continuously, and three dosage group NK cells in mice activity are compared with negative control, and learn by statistics and process, there was no significant difference (P〉0.05).The present invention is aobvious negative to the NK cytoactive result of the test of mouse.
5. sum up
The continuous gavage mouse of the present invention had no significant effect Mouse Weight after 30 days; Test for celluar immunity result to mouse is negative; NK test cell line result to mouse is negative; To the test for humoral immunity of mouse, the hemolysis plaque number of three dosage groups and negative control group compare, and low, middle dosage group difference all has conspicuousness (P＜0.05), and result of the test is positive; To the monocytes/macrophages phagocytic function test of mouse, the phagocytic rate of three dosage group mouse and phagocytic index and negative control group compare, and middle and high dosage group difference has conspicuousness (P＜0.05), and result of the test is positive.
Can judge according to " health food check and assessment technique standard " version in 2003, the present invention has the function that improves immunity to animal.
Embodiment 7:
The present invention improves the stressed function zoopery of anti-anoxic
1 sample and method
1.1 sample is provided by the Wuxi City health bio tech ltd of being bestowed by heaven.
1.2 120 of animal used as test male mice in kunming, body weight 18 ~ 20g.
1.3 it is 50ml/60kgBW that dosage is selected human body recommended amounts every day, 2 times of concentrates of this experiment employing are established 4.17ml/60kgBW, 8.33ml/60kgBW, three dosage groups of 12.50ml/60kgBW (be equivalent to respectively human body recommended amounts 10,20,30 times).Measure respectively 2 times of concentrate 52.1ml, 104.2ml, 156.3ml, each adding distil water is settled to the 250ml mixing, and refrigerator-freezer is preserved, and is finished and joins, and other establishes the distilled water control group.Experiment is divided into one, two, three group, every group of 40 animals.
1.4 experimental technique
1.4.1 with distillation water as solvent preparation tested material, press once a day per os gavage mouse of 20ml/60kgBW, give continuously 30 days.
1.4.2 the normal pressure hypoxia endurance test will be tested the animal last of one group of each dosage group and give after the tested material 1 hour, each dosage group mouse is put into respectively the 250ml port grinding bottle (1 every bottle) that fills the 5g soda lime, seal bottleneck with vaseline, cover tightly, make it air tight, immediately timing take breath stopped as index, is observed mouse because of the anoxic Post-dead duration.
1.4.3 natrium nitrosum poisoning survival test will be tested the animal last of two groups of each dosage groups and give after the tested material 1 hour, with each dosage group mouse by 220mg/60kgBW dosage lumbar injection natrium nitrosum (injection volume is 0.1ml/10g), immediately timing, the record animals survived time.
1.4.4 the Ischemia Injury in Brain hypoxia test will be tested the animal last of three groups of each dosage groups and give after the tested material 1 hour, with each dosage group mouse from neck by broken end only, immediately by behind the stopwatch record mouse broken end to the dwell time of breathing of dehiscing.
1.5 the data statistics of test data statistical test adopts SPSS 11.0 for windows software kits to process, data are through the variance test of homogeneity, and variance is neat, carries out variance analysis,, then compares in twos with the Dunnett method less than 0.05 such as the P value; If heterogeneity of variance then carries out data transaction, and is still uneven, use rank test instead,, then compare in twos with the Dunnett'sT3 method less than 0.05 such as the P value.
2 results
2.1 the present invention is on the impact of Mouse Weight
By table 12,13,14 as seen, the initial body weight of each dosage group and control animals is learned processing by statistics, variance neat (P〉0.05), and the results of analysis of variance (P〉0.05), show that the initial body weight of each treated animal is balanced.Body weight and control group were relatively learned by statistics and are processed when the mid-term of three dosage treated animals, body weight was with end, difference that there are no significant (P〉0.05).
Table 12 take the present invention respectively organize the initial body weight of mouse (
)
Table 13 take the present invention respectively organize mouse body weight in mid-term (
)
Table 14 take the present invention respectively organize mouse finish body weight (
)
2.2 the present invention is on the impact of mouse Hypoxia under normal pressure
By as seen from Table 15, the mouse Hypoxia under normal pressure of three dosage groups and control group are relatively learned by statistics and are processed, difference that there are no significant (P〉0.05).
Table 15 take the present invention on the impact of mouse Hypoxia under normal pressure (
)
2.3 the present invention is on the impact of poisoning time-to-live of mouse natrium nitrosum
By as seen from Table 16, the mouse natrium nitrosum of three dosage groups is poisoned time-to-live and control group relatively, learns by statistics processing, and the poisoning prolonged survival period of basic, normal, high dosage group all has significant difference (P＜0.05).
Table 16 take the present invention on the mouse natrium nitrosum poison the time-to-live impact (
)
2.4 the present invention is on the impact of anoxic time of chmice acute cerebral ischemia
By as seen from Table 17, the chmice acute cerebral ischemia the survival time under hypoxic condition of three dosage groups and control group are relatively learned by statistics and are processed, the Ischemia Injury in Brain the survival time under hypoxic condition of basic, normal, high dosage group prolongs all significant difference (P 0.05).
Table 17 take the present invention on the impact of anoxic time of chmice acute cerebral ischemia (
)
3 brief summaries
After continuous 30 days per os gavages of the present invention gave male mice, visible growth of animal was good, the body weight sustainable growth.The result is negative for the normal pressure hypoxia endurance test; Basic, normal, high dosage group can obviously prolong natrium nitrosum and poison the time-to-live, and the result is positive for natrium nitrosum poisoning survival test; Basic, normal, high dosage group can obviously prolong chmice acute cerebral ischemia the survival time under hypoxic condition, the result is positive to the Ischemia Injury in Brain hypoxia test, by the regulation in " health food check and assessment technique standard " (version in 2003), the present invention has the raising anoxia tolerant function to animal.
Claims (5)
1. one kind has the health food that improves immunity and resisting oxygen lack simultaneously, it is characterized in that, is comprised of the component of following percentage by weight: 5 ~ 45% ginkgo, 5 ~ 30% the red sage root, 10 ~ 50% sea-buckthorn, 5 ~ 20% rhodiola root and 5 ~ 20% pseudo-ginseng.
2. according to claim 1 have the health food that improves immunity and resisting oxygen lack simultaneously, it is characterized in that, is comprised of the component of following percentage by weight: 25% ginkgo, 18% the red sage root, 33% sea-buckthorn, 12% rhodiola root and 12% pseudo-ginseng.
3. the health food that has simultaneously raising immunity and resisting oxygen lack according to claim 1 is characterized in that, makes tablet, capsule, oral liquid or soft capsule.
4. prepare claim 1 or the 2 described methods that have simultaneously the health food that improves immunity and resisting oxygen lack, it is characterized in that, may further comprise the steps: measure each raw material by prescription, crushing screening, add the dolomol of raw material gross weight 1 ~ 2% and 1 ~ 2% silica, mixed 15 ~ 20 minutes, and poured into capsule and get final product.
5. preparation according to claim 4 has the method for the health food that improves immunity and resisting oxygen lack simultaneously, it is characterized in that described sieve≤100 orders.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105165073A CN103039977A (en) | 2012-12-05 | 2012-12-05 | Healthcare food with functions of immunity improvement and hypoxia tolerance and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105165073A CN103039977A (en) | 2012-12-05 | 2012-12-05 | Healthcare food with functions of immunity improvement and hypoxia tolerance and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103039977A true CN103039977A (en) | 2013-04-17 |
Family
ID=48053022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012105165073A Pending CN103039977A (en) | 2012-12-05 | 2012-12-05 | Healthcare food with functions of immunity improvement and hypoxia tolerance and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103039977A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103735603A (en) * | 2014-02-11 | 2014-04-23 | 武汉市元大生物科技有限公司 | Compound lipid-decreasing soft capsule and preparation method thereof |
| CN104187724A (en) * | 2014-08-21 | 2014-12-10 | 安徽广印堂中药股份有限公司 | Pseudo-ginseng health product and preparation method thereof |
| CN108013450A (en) * | 2017-12-01 | 2018-05-11 | 绵阳正耀久生物科技有限公司 | It is a kind of that there are the health products for improving immune function |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101856119A (en) * | 2010-03-23 | 2010-10-13 | 无锡市天赐康生物科技有限公司 | Health-care food for relieving physical fatigue and resisting radiation hazard and preparation method thereof |
| CN101940313A (en) * | 2010-03-25 | 2011-01-12 | 无锡市天赐康生物科技有限公司 | Health food capable of enhancing immunity of human body and preparation method thereof |
-
2012
- 2012-12-05 CN CN2012105165073A patent/CN103039977A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101856119A (en) * | 2010-03-23 | 2010-10-13 | 无锡市天赐康生物科技有限公司 | Health-care food for relieving physical fatigue and resisting radiation hazard and preparation method thereof |
| CN101940313A (en) * | 2010-03-25 | 2011-01-12 | 无锡市天赐康生物科技有限公司 | Health food capable of enhancing immunity of human body and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| XIAOWU1987831: "三七银杏茶http://wenku.baidu.com/view/34c764ff0242a8956bece4f4.html", 《百度文库》, no. 01, 9 May 2012 (2012-05-09) * |
| 无: "应新康牌人参三七银杏茶益寿养生http://yk4589.b2b.youboy.com/show0sp13556747.html", 《银杏茶生产供应商》, no. 01, 5 February 2012 (2012-02-05) * |
| 无锡市天赐康生物科技有限公司: "威华牌银杏三七胶囊http://app1.sfda.gov.cn/datasearch/face3/base.jsp?tableId=31&tableName=TABLE31&title=%BD%F8%BF%DA%B1%A3%BD%A1%CA%B3%C6%B7&bcId=118103387241329685908587941736", 《国家食品药品监督管理局--数据查询》, no. 1, 11 May 2011 (2011-05-11) * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103735603A (en) * | 2014-02-11 | 2014-04-23 | 武汉市元大生物科技有限公司 | Compound lipid-decreasing soft capsule and preparation method thereof |
| CN103735603B (en) * | 2014-02-11 | 2016-08-31 | 武汉市元大生物科技有限公司 | A kind of compound antihyperglycemic soft capsule and preparation method thereof |
| CN104187724A (en) * | 2014-08-21 | 2014-12-10 | 安徽广印堂中药股份有限公司 | Pseudo-ginseng health product and preparation method thereof |
| CN104187724B (en) * | 2014-08-21 | 2016-05-25 | 安徽广印堂中药股份有限公司 | A kind of Radix Notoginseng health products and preparation method thereof |
| CN108013450A (en) * | 2017-12-01 | 2018-05-11 | 绵阳正耀久生物科技有限公司 | It is a kind of that there are the health products for improving immune function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103169079A (en) | Health-care food with anti-fatigue and immunity-enhancing effects, and preparation method thereof | |
| CN101595988B (en) | Health-care food preparation for alleviating fatigue and preparation method thereof | |
| CN102960715A (en) | Immunity-enhancing and hypoxia tolerant health food and preparation method thereof | |
| CN101248880B (en) | Fatigue resistant sport drink and method of preparing the same | |
| CN103343083A (en) | Liver protecting and hangover alleviating fruit vinegar and preparation method thereof | |
| CN103300446A (en) | Functional blueberry beverage composition | |
| CN101856112A (en) | Health food for enhancing immune function of human body and preparation method thereof | |
| US20220087926A1 (en) | Compound composition with anti-oxidation and anti-aging effects and preparation method and application thereof | |
| CN101805688B (en) | Mulberry health-care wine and preparation method thereof | |
| CN104026563A (en) | Composition having muscle power fatigue alleviating and anoxic tolerance improving effects, and preparation method thereof | |
| CN103829234A (en) | Health food capable of improving immunity and reducing blood fat and preparation method thereof | |
| CN108157575A (en) | A kind of pressed candy for alleviating visual fatigue and preparation method and application | |
| CN101810657B (en) | American ginseng contained composition and American ginseng tea drink | |
| CN102871120A (en) | Heath-care food for improving human immunity and preparation method thereof | |
| CN102429150A (en) | Vitamin C chewable tablets for enhancing human immunity | |
| CN103039977A (en) | Healthcare food with functions of immunity improvement and hypoxia tolerance and preparation method thereof | |
| CN102860496B (en) | Oxidation-resisting health-care food for improving immunity and preparation method thereof | |
| CN103584091B (en) | A kind of guarantor with raising immunity, hypolipemic function builds food and preparation method thereof | |
| CN102885307B (en) | Composition for damp-heat constitutions, preparation method and applications thereof | |
| CN102860495B (en) | Anti-anoxia immunity-improving health food and preparation method thereof | |
| CN104189038B (en) | Chinese medicine preparation for nursing one's health female pathology health and immunologic function | |
| CN102871119A (en) | Health-care food with anti-anoxia effect and preparation method thereof | |
| CN101015345A (en) | Health-care food with hypoxia-resistant and immunity-enhancing functions and its preparing process | |
| CN101940317B (en) | Health food for improving immunity of human bodies and preparation method thereof | |
| CN102860509A (en) | Anti-fatigue immunity-improving health food and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130417 |